Nautilus Biotechnology (NASDAQ:NAUT) and Bio-Techne (NASDAQ:TECH) Head to Head Contrast

Bio-Techne (NASDAQ:TECH) and Nautilus Biotechnology (NASDAQ:NAUT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Institutional and Insider Ownership

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Bio-Techne and Nautilus Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Earnings & Valuation

This table compares Bio-Techne and Nautilus Biotechnology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22 billion	9.25	$73.40 million	$0.69	104.48
Nautilus Biotechnology	N/A	N/A	-$59.00 million	($0.45)	-2.17

Bio-Techne has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bio-Techne has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Bio-Techne and Nautilus Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1	13	3	0	2.12
Nautilus Biotechnology	1	0	1	0	2.00

Bio-Techne currently has a consensus price target of $68.08, suggesting a potential downside of 5.57%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 309.42%. Given Nautilus Biotechnology’s higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Bio-Techne.

Summary

Bio-Techne beats Nautilus Biotechnology on 11 of the 13 factors compared between the two stocks.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.